Interactome Biotherapeutics

Executive Summary

Interactome Biotherapeutics is pioneering a next-generation biologic platform based on a multi-targeted Secretome—a complex mixture of hundreds of biologically active proteins and factors that drive cellular regeneration, modulate inflammation, and support cell recovery and turnover. Founded in 2019 and headquartered in Cambridge, MA, the company aims to address significant unmet needs in neurology, oncology, and cardiology. Unlike conventional single-target biologics, Interactome's platform leverages the natural synergy of secreted proteins to potentially achieve broader efficacy and improved safety profiles. The technology is still in preclinical development, but the company has attracted attention for its novel approach to treating degenerative and inflammatory conditions.

Upcoming Catalysts (preview)

• Q2 2027Lead Program IND Filing for Neurological Indication40% success
• H1 2027Preclinical Proof-of-Concept Data in Oncology50% success
• 2026Strategic Partnership or Licensing Deal for Secretome Platform35% success